Background
High-mobility group box-1 (HMGB1) is an intranuclear molecule that is released extracellularly in cytotoxic conditions. In acute pancreatitis, extracellular HMGB1 acts as stimulating factor in the mechanism associated with pancreatic injury. The serum level of HMGB1 may be associated with the severity and prognosis of pancreatitis.
Methods
To evaluate the prognostic property of serum HMGB1 levels at the time of diagnosis of pancreatitis, case control study using serum samples collected over 10 months from canine patients in Seoul National University Veterinary Medical Teaching Hospital (SNU VMTH). The HMGB1 levels in serum were measured by ELSIA and they were analyzed with patient’s death, hospitalization cost and hospitalization period.
Results
Serum levels of HMGB1 in patients with acute pancreatitis (n=19) were higher than those in normal individuals (n=10). Mean (± standard deviation) values were 76.00 (±46.99) and 31.65 (±18.41) ng/mL, respectively (p=0.004). The levels of HMGB1 were significantly higher in non-survivors than in survivors with acute pancreatitis (p = 0.019). Clinical severity of acute pancreatitis was categorized into three stages—mild, moderate, and severe—based on the disease activity index (DAI). Higher HMGB1 levels in serum were related to mortality in patients with moderate DAI (p = 0.049). Furthermore, higher levels of serum HMGB1 among hospitalized patients were positively associated with higher costs and longer duration of hospital stays.
Conclusions
The evaluation of serum HMGB1 levels at the time of diagnosis was identified as a potential prognostic factor to assess the outcome of acute pancreatitis in canines.